Literature DB >> 10509802

Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.

C L Coulter1, R E Smith, M Stowasser, H Sasano, Z S Krozowski, R D Gordon.   

Abstract

The aim of this study was to investigate the ontogeny of localization of 11betaHSD-2 protein in the human adrenal gland. In addition, we have investigated the effects of abnormal adrenal function on 11betaHSD-2 by determining the pattern of localization of 11betaHSD-2 protein, and the amount and level of expression of 11betaHSD-2 mRNA and protein in human adrenal cortical carcinoma and adenoma. In the human foetal adrenal gland 11betaHSD-2 immunoreactivity (11betaHSD-2-ir) was detected in the foetal zone, whereas in normal adult adrenal glands 11betaHSD-2-ir was not detected by immunocytochemistry. In adrenal cortical carcinoma and adenoma, 11betaHSD-2-ir was detectable in specific regions, which have been identified as steroid synthesizing cells using 3betaHSD-ir as a marker. In adrenal cortical carcinoma and adenoma, 11betaHSD-2 mRNA and 11betaHSD-2 protein were detected by nuclease protection analysis and by western blot analysis, respectively. In summary, 11betaHSD-2-ir was detected in the foetal zone of the mid-gestation human foetal adrenal, whereas, 11betaHSD-2-ir was not detectable in the postnatal or normal adult adrenal gland. 11BetaHSD-2 protein and mRNA was induced in adult human adrenal cortical carcinoma and adenoma. The induction of expression of 11betaHSD-2 in the adrenal cortex suggests a possible role in regulating abnormal adrenal steroidogenic function in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509802     DOI: 10.1016/s0303-7207(99)00077-5

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit.

Authors:  Hitoshi Ishimoto; Robert B Jaffe
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

2.  Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells.

Authors:  Shuji Sai; Yuichi Nakagawa; Rie Yamaguchi; Masako Suzuki; Kimiyoshi Sakaguchi; Shuichi Okada; Jonathan R Seckl; Takehiko Ohzeki; Karen E Chapman
Journal:  Leuk Res       Date:  2011-07-26       Impact factor: 3.156

3.  Maternal melatonin selectively inhibits cortisol production in the primate fetal adrenal gland.

Authors:  Claudia Torres-Farfan; Hans G Richter; Alfredo M Germain; Guillermo J Valenzuela; Carmen Campino; Pedro Rojas-García; María Luisa Forcelledo; Fernando Torrealba; María Serón-Ferré
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

4.  Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.

Authors:  Alicia Subtil-Rodríguez; Lluís Millán-Ariño; Ignacio Quiles; Cecilia Ballaré; Miguel Beato; Albert Jordan
Journal:  Mol Cell Biol       Date:  2008-03-31       Impact factor: 4.272

5.  11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.

Authors:  Shilin Yang; Li Jiang; Ming-Zhi Zhang
Journal:  J Oncobiomarkers       Date:  2013

Review 6.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

7.  11ß hydroxysteroid dehydrogenases regulate circulating glucocorticoids but not central gene expression.

Authors:  Michelle A Rensel; Barney A Schlinger
Journal:  Gen Comp Endocrinol       Date:  2021-02-04       Impact factor: 2.822

Review 8.  Intracrine androgen biosynthesis, metabolism and action revisited.

Authors:  Lina Schiffer; Wiebke Arlt; Karl-Heinz Storbeck
Journal:  Mol Cell Endocrinol       Date:  2017-09-01       Impact factor: 4.102

9.  Harnessing the gatekeepers of glucocorticoids for chemoprevention of non-melanoma skin cancer.

Authors:  Anna M Mancha-Ramirez; Xiaoyu Yang; Huiyun Liang; Jacob Junco; Kevin P Lee; Sarah F Bovio; Maricruz Espinoza; Julia Wool; Andrew Slaga; Daniel C Glade; Martha Hanes; Gunjan Malik; Dae Joon Kim; John DiGiovanni; Thomas J Slaga
Journal:  Mol Carcinog       Date:  2018-10-09       Impact factor: 4.784

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.